Immune Cell Inhibition by SLAMF7 Is Mediated by a Mechanism Requiring Src Kinases, CD45, and SHIP-1 That Is Defective in Multiple Myeloma Cells

REFERENCES

• Veillette A, Guo H. 2013. CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma. Crit Rev Oncol Hematol 88:168–177. http://dx.doi.org/10.1016/j.critrevonc.2013.04.003.
   PubMed Web of Science ®Google Scholar
• Bouchon A, Cella M, Grierson HL, Cohen JI, Colonna M. 2001. Activation of NK cell-mediated cytotoxicity by a SAP-independent receptor of the CD2 family. J Immunol 167:5517–5521. http://dx.doi.org/10.4049/jimmunol.167.10.5517.
   PubMed Web of Science ®Google Scholar
• Hsi ED, Steinle R, Balasa B, Szmania S, Draksharapu A, Shum BP, Huseni M, Powers D, Nanisetti A, Zhang Y, Rice AG, van Abbema A, Wong M, Liu G, Zhan F, Dillon M, Chen S, Rhodes S, Fuh F, Tsurushita N, Kumar S, Vexler V, Shaughnessy JD, Jr, Barlogie B, van Rhee F, Hussein M, Afar DE, Williams MB. 2008. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res 14:2775–2784. http://dx.doi.org/10.1158/1078-0432.CCR-07-4246.
   PubMed Web of Science ®Google Scholar
• Tai YT, Dillon M, Song W, Leiba M, Li XF, Burger P, Lee AI, Podar K, Hideshima T, Rice AG, van Abbema A, Jesaitis L, Caras I, Law D, Weller E, Xie W, Richardson P, Munshi NC, Mathiot C, Avet-Loiseau H, Afar DE, Anderson KC. 2008. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 112:1329–1337. http://dx.doi.org/10.1182/blood-2007-08-107292.
   PubMed Web of Science ®Google Scholar
• Cruz-Munoz ME, Dong Z, Shi X, Zhang S, Veillette A. 2009. Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function. Nat Immunol 10:297–305. http://dx.doi.org/10.1038/ni.1693.
   PubMed Web of Science ®Google Scholar
• Tassi I, Colonna M. 2005. The cytotoxicity receptor CRACC (CS-1) recruits EAT-2 and activates the PI3K and phospholipase Cgamma signaling pathways in human NK cells. J Immunol 175:7996–8002. http://dx.doi.org/10.4049/jimmunol.175.12.7996.
   PubMed Web of Science ®Google Scholar
• Perez-Quintero LA, Roncagalli R, Guo H, Latour S, Davidson D, Veillette A. 2014. EAT-2, a SAP-like adaptor, controls NK cell activation through phospholipase Cgamma, Ca++, and Erk, leading to granule polarization. J Exp Med 211:727–742. http://dx.doi.org/10.1084/jem.20132038.
   PubMed Web of Science ®Google Scholar
• van Rhee F, Szmania SM, Dillon M, van Abbema AM, Li X, Stone MK, Garg TK, Shi J, Moreno-Bost AM, Yun R, Balasa B, Ganguly B, Chao D, Rice AG, Zhan F, Shaughnessy JD, Jr, Barlogie B, Yaccoby S, Afar DE. 2009. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther 8:2616–2624. http://dx.doi.org/10.1158/1535-7163.MCT-09-0483.
   PubMed Web of Science ®Google Scholar
• Zonder JA, Mohrbacher AF, Singhal S, van Rhee F, Bensinger WI, Ding H, Fry J, Afar DE, Singhal AK. 2012. A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood 120:552–559. http://dx.doi.org/10.1182/blood-2011-06-360552.
   PubMed Web of Science ®Google Scholar
• Jakubowiak AJ, Benson DM, Bensinger W, Siegel DS, Zimmerman TM, Mohrbacher A, Richardson PG, Afar DE, Singhal AK, Anderson KC. 2012. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J Clin Oncol 30:1960–1965. http://dx.doi.org/10.1200/JCO.2011.37.7069.
   PubMed Web of Science ®Google Scholar
• Lonial S, Vij R, Harousseau JL, Facon T, Moreau P, Mazumder A, Kaufman JL, Leleu X, Tsao LC, Westland C, Singhal AK, Jagannath S. 2012. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol 30:1953–1959. http://dx.doi.org/10.1200/JCO.2011.37.2649.
   PubMed Web of Science ®Google Scholar
• Lonial S, Kaufman J, Laubach J, Richardson P. 2013. Elotuzumab: a novel anti-CS1 monoclonal antibody for the treatment of multiple myeloma. Expert Opin Biol Ther 13:1731–1740. http://dx.doi.org/10.1517/14712598.2013.847919.
   PubMed Web of Science ®Google Scholar
• Collins SM, Bakan CE, Swartzel GD, Hofmeister CC, Efebera YA, Kwon H, Starling GC, Ciarlariello D, Bhaskar S, Briercheck EL, Hughes T, Yu J, Rice A, Benson DM, Jr. 2013. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunol Immunother 62:1841–1849. http://dx.doi.org/10.1007/s00262-013-1493-8.
   PubMed Web of Science ®Google Scholar
• Roncagalli R, Taylor JE, Zhang S, Shi X, Chen R, Cruz-Munoz ME, Yin L, Latour S, Veillette A. 2005. Negative regulation of natural killer cell function by EAT-2, a SAP-related adaptor. Nat Immunol 6:1002–1010. http://dx.doi.org/10.1038/ni1242.
   PubMed Web of Science ®Google Scholar
• Dong Z, Davidson D, Perez-Quintero LA, Kurosaki T, Swat W, Veillette A. 2012. The adaptor SAP controls NK cell activation by regulating the enzymes Vav-1 and SHIP-1 and by enhancing conjugates with target cells. Immunity 36:974–985. http://dx.doi.org/10.1016/j.immuni.2012.03.023.
   PubMed Web of Science ®Google Scholar
• Weber M, Treanor B, Depoil D, Shinohara H, Harwood NE, Hikida M, Kurosaki T, Batista FD. 2008. Phospholipase C-gamma2 and Vav cooperate within signaling microclusters to propagate B cell spreading in response to membrane-bound antigen. J Exp Med 205:853–868. http://dx.doi.org/10.1084/jem.20072619.
   PubMed Web of Science ®Google Scholar
• Dong Z, Cruz-Munoz ME, Zhong MC, Chen R, Latour S, Veillette A. 2009. Essential function for SAP family adaptors in the surveillance of hematopoietic cells by natural killer cells. Nat Immunol 10:973–980. http://dx.doi.org/10.1038/ni.1763.
   PubMedGoogle Scholar
• Desai DM, Sap J, Schlessinger J, Weiss A. 1993. Ligand-mediated negative regulation of a chimeric transmembrane receptor tyrosine phosphatase. Cell 73:541–554. http://dx.doi.org/10.1016/0092-8674(93)90141-C.
   PubMed Web of Science ®Google Scholar
• Latour S, Fournel M, Veillette A. 1997. Regulation of T-cell antigen receptor signalling by Syk tyrosine protein kinase. Mol Cell Biol 17:4434–4441.
   PubMedGoogle Scholar
• Fuchs A, Cella M, Giurisato E, Shaw AS, Colonna M. 2004. Cutting edge: CD96 (tactile) promotes NK cell-target cell adhesion by interacting with the poliovirus receptor (CD155). J Immunol 172:3994–3998. http://dx.doi.org/10.4049/jimmunol.172.7.3994.
   PubMed Web of Science ®Google Scholar
• Veillette A, Bookman MA, Horak EM, Bolen JB. 1988. The CD4 and CD8 T cell surface antigens are associated with the internal membrane tyrosine-protein kinase p56lck. Cell 55:301–308. http://dx.doi.org/10.1016/0092-8674(88)90053-0.
   PubMed Web of Science ®Google Scholar
• Lee JK, Boles KS, Mathew PA. 2004. Molecular and functional characterization of a CS1 (CRACC) splice variant expressed in human NK cells that does not contain immunoreceptor tyrosine-based switch motifs. Eur J Immunol 34:2791–2799. http://dx.doi.org/10.1002/eji.200424917.
   PubMed Web of Science ®Google Scholar
• Veillette A. 2010. SLAM-family receptors: immune regulators with or without SAP-family adaptors. Cold Spring Harb Perspect Biol 2:a002469. http://dx.doi.org/10.1101/cshperspect.a002469.
   PubMed Web of Science ®Google Scholar
• Cannons JL, Tangye SG, Schwartzberg PL. 2011. SLAM family receptors and SAP adaptors in immunity. Annu Rev Immunol 29:665–705. http://dx.doi.org/10.1146/annurev-immunol-030409-101302.
   PubMed Web of Science ®Google Scholar
• Veillette A, Latour S. 2003. The SLAM family of immune-cell receptors. Curr Opin Immunol 15:277–285. http://dx.doi.org/10.1016/S0952-7915(03)00041-4.
   PubMed Web of Science ®Google Scholar
• Sayos J, Martin M, Chen A, Simarro M, Howie D, Morra M, Engel P, Terhorst C. 2001. Cell surface receptors Ly-9 and CD84 recruit the X-linked lymphoproliferative disease gene product SAP. Blood 97:3867–3874. http://dx.doi.org/10.1182/blood.V97.12.3867.
   PubMedGoogle Scholar
• Galandrini R, Tassi I, Mattia G, Lenti L, Piccoli M, Frati L, Santoni A. 2002. SH2-containing inositol phosphatase (SHIP-1) transiently translocates to raft domains and modulates CD16-mediated cytotoxicity in human NK cells. Blood 100:4581–4589. http://dx.doi.org/10.1182/blood-2002-04-1058.
   PubMedGoogle Scholar
• Banh C, Miah SM, Kerr WG, Brossay L. 2012. Mouse natural killer cell development and maturation are differentially regulated by SHIP-1. Blood 120:4583–4590. http://dx.doi.org/10.1182/blood-2012-04-425009.
   PubMedGoogle Scholar
• Kurosaki T. 1999. Genetic analysis of B cell antigen receptor signaling. Annu Rev Immunol 17:555–592. http://dx.doi.org/10.1146/annurev.immunol.17.1.555.
   PubMed Web of Science ®Google Scholar
• Lee JK, Mathew SO, Vaidya SV, Kumaresan PR, Mathew PA. 2007. CS1 (CRACC, CD319) induces proliferation and autocrine cytokine expression on human B lymphocytes. J Immunol 179:4672–4678. http://dx.doi.org/10.4049/jimmunol.179.7.4672.
   PubMed Web of Science ®Google Scholar
• Kim JR, Mathew SO, Patel RK, Pertusi RM, Mathew PA. 2010. Altered expression of signalling lymphocyte activation molecule (SLAM) family receptors CS1 (CD319) and 2B4 (CD244) in patients with systemic lupus erythematosus. Clin Exp Immunol 160:348–358. http://dx.doi.org/10.1111/j.1365-2249.2010.04116.x.
   PubMed Web of Science ®Google Scholar
• Shrivastava P, Katagiri T, Ogimoto M, Mizuno K, Yakura H. 2004. Dynamic regulation of Src-family kinases by CD45 in B cells. Blood 103:1425–1432. http://dx.doi.org/10.1182/blood-2003-03-0716.
   PubMed Web of Science ®Google Scholar
• Zhu JW, Brdicka T, Katsumoto TR, Lin J, Weiss A. 2008. Structurally distinct phosphatases CD45 and CD148 both regulate B cell and macrophage immunoreceptor signaling. Immunity 28:183–196. http://dx.doi.org/10.1016/j.immuni.2007.11.024.
   PubMedGoogle Scholar
• Rhee I, Veillette A. 2012. Protein tyrosine phosphatases in lymphocyte activation and autoimmunity. Nat Immunol 13:439–447. http://dx.doi.org/10.1038/ni.2246.
   PubMed Web of Science ®Google Scholar
• Hesslein DG, Takaki R, Hermiston ML, Weiss A, Lanier LL. 2006. Dysregulation of signaling pathways in CD45-deficient NK cells leads to differentially regulated cytotoxicity and cytokine production. Proc Natl Acad Sci U S A 103:7012–7017. http://dx.doi.org/10.1073/pnas.0601851103.
   PubMedGoogle Scholar
• Martin SM, Mehta IK, Yokoyama WM, Thomas ML, Lorenz RG. 2001. Development of intestinal intraepithelial lymphocytes, NK cells, and NK 11+ T cells in CD45-deficient mice. J Immunol 166:6066–6073. http://dx.doi.org/10.4049/jimmunol.166.10.6066.
   PubMedGoogle Scholar
• Yamada H, Kishihara K, Kong YY, Nomoto K. 1996. Enhanced generation of NK cells with intact cytotoxic function in CD45 exon 6-deficient mice. J Immunol 157:1523–1528.
   PubMedGoogle Scholar
• Lakshmikanth T, Burke S, Ali TH, Kimpfler S, Ursini F, Ruggeri L, Capanni M, Umansky V, Paschen A, Sucker A, Pende D, Groh V, Biassoni R, Hoglund P, Kato M, Shibuya K, Schadendorf D, Anichini A, Ferrone S, Velardi A, Karre K, Shibuya A, Carbone E, Colucci F. 2009. NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest 119:1251–1263. http://dx.doi.org/10.1172/JCI36022.
   PubMed Web of Science ®Google Scholar
• Gilfillan S, Chan CJ, Cella M, Haynes NM, Rapaport AS, Boles KS, Andrews DM, Smyth MJ, Colonna M. 2008. DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J Exp Med 205:2965–2973. http://dx.doi.org/10.1084/jem.20081752.
   PubMed Web of Science ®Google Scholar
• Iguchi-Manaka A, Kai H, Yamashita Y, Shibata K, Tahara-Hanaoka S, Honda S, Yasui T, Kikutani H, Shibuya K, Shibuya A. 2008. Accelerated tumor growth in mice deficient in DNAM-1 receptor. J Exp Med 205:2959–2964. http://dx.doi.org/10.1084/jem.20081611.
   PubMedGoogle Scholar
• Kageyama R, Cannons JL, Zhao F, Yusuf I, Lao C, Locci M, Schwartzberg PL, Crotty S. 2012. The receptor Ly108 functions as a SAP adaptor-dependent on-off switch for T cell help to B cells and NKT cell development. Immunity 36:986–1002. http://dx.doi.org/10.1016/j.immuni.2012.05.016.
   PubMedGoogle Scholar
• Zhao F, Cannons JL, Dutta M, Griffiths GM, Schwartzberg PL. 2012. Positive and negative signaling through SLAM receptors regulate synapse organization and thresholds of cytolysis. Immunity 36:1003–1016. http://dx.doi.org/10.1016/j.immuni.2012.05.017.
   PubMed Web of Science ®Google Scholar
• Kumar S, Rajkumar SV, Kimlinger T, Greipp PR, Witzig TE. 2005. CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations. Leukemia 19:1466–1470. http://dx.doi.org/10.1038/sj.leu.2403823.
   PubMed Web of Science ®Google Scholar
• Moreau P, Robillard N, Avet-Loiseau H, Pineau D, Morineau N, Milpied N, Harousseau JL, Bataille R. 2004. Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma. Haematologica 89:547–551.
   PubMed Web of Science ®Google Scholar
• Pellat-Deceunynck C, Bataille R. 2004. Normal and malignant human plasma cells: proliferation, differentiation, and expansions in relation to CD45 expression. Blood Cells Mol Dis 32:293–301. http://dx.doi.org/10.1016/j.bcmd.2003.12.001.
   PubMed Web of Science ®Google Scholar
• Kim D, Park CY, Medeiros BC, Weissman IL. 2012. CD19−CD45low/−CD38high/CD138+ plasma cells enrich for human tumorigenic myeloma cells. Leukemia 26:2530–2537. http://dx.doi.org/10.1038/leu.2012.140.
   PubMed Web of Science ®Google Scholar
• Descamps G, Pellat-Deceunynck C, Szpak Y, Bataille R, Robillard N, Amiot M. 2004. The magnitude of Akt/phosphatidylinositol 3′-kinase proliferating signaling is related to CD45 expression in human myeloma cells. J Immunol 173:4953–4959. http://dx.doi.org/10.4049/jimmunol.173.8.4953.
   PubMed Web of Science ®Google Scholar